Program
obinutuzumab
Also written as “Obinutuzumab”, “Obinutuzumab, naptumomab estafenatox and durvalumab” and “obinutuzumab (RO5072759)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lupus Nephritis · Lupus Erythematosus, Systemic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 325 open or running | phase 4since Jan 24, 2019 | Aug 16, 2007 | Dec 28, 2026phase 2 · NCT04077723 |
| AbbVie | 32 open or running | phase 3since May 20, 2024 | May 19, 2021 | Nov 2026phase 2 · NCT04895436 |
Also a collaborator on its studies: AstraZeneca and roche-pharma-ag.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Aug 16, 2007.
- Nov 3, 2015Phase 2 study in RecurrenceHoffmann-La Roche · NCT02600897 · 114 enrolled · United States, Spain, United Kingdom
- Dec 1, 2015Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT02624986 · 25 enrolled · United States, Australia, Germany and more
- Jan 24, 2019Phase 4 study in Advanced Follicular LymphomaHoffmann-La Roche · NCT03817853 · 114 enrolled · United States, Brazil, Germany and more
- Mar 6, 2019Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT03866239 · 47 enrolled · United States, Denmark, France and more
- Aug 9, 2019Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT04077723 · 498 enrolled · United States, Australia, Belgium and more
- Jan 7, 2020Phase 3 study in Lupus NephritisHoffmann-La Roche · NCT04221477 · 271 enrolled · United States, Argentina, Brazil and more
- Feb 25, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT04285567 · 166 enrolled · United States, Australia, France and more
- Oct 27, 2020Phase 3 study in Primary Membranous NephropathyHoffmann-La Roche · NCT04629248 · 142 enrolled · United States, Argentina, Brazil and more
- May 19, 2021AbbVie's first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AbbVieAbbVie · NCT04895436 · 75 planned · United States, Australia, Austria and more
- Jul 7, 2021Phase 3 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT04963296 · 303 enrolled · United States, Argentina, Brazil and more
- Sep 1, 2021Phase 2 study in Lupus NephritisHoffmann-La Roche · NCT05039619 · 40 planned · United States, Brazil, Canada and more
- Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT05105841 · 20 enrolled · Japan
- Nov 4, 2022Phase 3 study in Nephrotic SyndromeHoffmann-La Roche · NCT05627557 · 85 enrolled · United States, Belgium, Brazil and more
- May 20, 2024Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT06428019 · 170 planned · United States, Australia, France and more
Ahead
- Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436
- Dec 28, 2026Primary completion: phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT04077723
- Mar 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT06428019
- Jun 15, 2028Primary completion: phase 2 study in Lupus NephritisHoffmann-La Roche · NCT05039619
TargetBeta
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Recruiting | AbbVie | Mar 2028 | 170 |
| NCT05627557Nephrotic Syndrome · United States, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Sep 4, 2025 | 85 |
| NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | AbbVie | Oct 9, 2025 | 20 |
| NCT05039619Lupus Nephritis · United States, Brazil, Canada and more | 2 | Recruiting | Hoffmann-La Roche | Jun 15, 2028 | 40 |
| NCT04963296Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Sep 15, 2025 | 303 |
| NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Recruiting | AbbVie | Nov 2026 | 75 |
| NCT04629248Primary Membranous Nephropathy · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Dec 22, 2025 | 142 |
| NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Completed | Hoffmann-La Roche | Mar 19, 2024 | 166 |
| NCT04221477Lupus Nephritis · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Aug 15, 2024 | 271 |
| NCT04077723Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 2 | Active, not recruiting | Hoffmann-La Roche | Dec 28, 2026 | 498 |
| NCT03866239Colorectal Neoplasms · United States, Denmark, France and more | 1 | Terminated | Hoffmann-La Roche | Mar 13, 2024 | 47 |
| NCT03817853Advanced Follicular Lymphoma · United States, Brazil, Germany and more | 4 | Completed | Hoffmann-La Roche | Aug 4, 2020 | 114 |
| NCT02624986Lymphoma, Non-Hodgkin · United States, Australia, Germany and more | 2 | Terminated | Hoffmann-La Roche | May 20, 2019 | 25 |
| NCT02600897Recurrence · United States, Spain, United Kingdom | 2 | Completed | Hoffmann-La Roche | Dec 15, 2021 | 114 |
| NCT02586051Kidney Failure, Chronic · United States | 1 | Completed | Hoffmann-La Roche | Nov 26, 2018 | 24 |
| NCT02550652Lupus Nephritis · United States, Argentina, Brazil and more | 2 | Completed | Hoffmann-La Roche | Jan 15, 2019 | 126 |
| NCT02320487Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Nov 7, 2016 | 102 |
| NCT02071225Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | Hoffmann-La Roche | Nov 19, 2018 | 72 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Hoffmann-La Roche | Jun 28, 2017 | 267 |
| NCT02053610Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2013 | 787 |
| NCT01998880Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Aug 1, 2012 | 787 |
| NCT01905943Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Belgium, Bosnia and Herzegovina and more | 3 | Completed | Hoffmann-La Roche | Dec 29, 2016 | 979 |
| NCT01868893Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Jan 2014 | 20 |
| NCT01691898Lymphoma, Follicular · United States, Canada, France and more | 2 | Completed | Hoffmann-La Roche | Mar 8, 2017 | 231 |
| NCT01685892Leukemia, Lymphocytic, Chronic, B-Cell · United States, United Kingdom | 1 | Completed | Hoffmann-La Roche | May 21, 2018 | 82 |
| NCT01680991Leukemia, Lymphoid · China | 1 | Completed | Hoffmann-La Roche | Dec 2014 | 48 |
| NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany | 1 | Completed | Hoffmann-La Roche | Aug 17, 2018 | 84 |
| NCT01414855Lymphoma, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Dec 31, 2013 | 100 |
| NCT01414205Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Mar 31, 2013 | 80 |
| NCT01332968Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Feb 1, 2016 | 1,401 |
| NCT01287741Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more | 3 | Terminated | Hoffmann-La Roche | Apr 29, 2016 | 1,418 |
| NCT01059630Lymphoma, Non-Hodgkin · United States, Austria, Belgium and more | 3 | Completed | Hoffmann-La Roche | Sep 30, 2014 | 413 |
| NCT01010061Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Jul 1, 2012 | 787 |
| NCT00576758Lymphoma, Non-Hodgkin · United States, Argentina, Austria and more | 2 | Completed | Hoffmann-La Roche | Sep 2011 | 175 |
| NCT00517530Lymphoma · France, Germany | 2 | Completed | Hoffmann-La Roche | Nov 2013 | 134 |
How it is read
Names in the registry
- “Obinutuzumab”, 35 entries
- “obinutuzumab”, 5 entries
- “Obinutuzumab, naptumomab estafenatox and durvalumab”, 1 entry
- “obinutuzumab (RO5072759)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
- Lymphoma, Non-Hodgkin, 6 studies
- Lymphoma, Follicular, 4 studies
- Lupus Nephritis, 3 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.